摘要
目的:探讨沙库巴曲缬沙坦钠片治疗高原地区慢性心力衰竭(CHF)患者的疗效及对神经内分泌激素和心功能的影响。方法:选取2017年3月2019年6月期间我院接收的CHF患者109例。根据随机数字表法将患者随机分为对照组(n=54)和研究组(n=55),对照组患者予以缬沙坦治疗,研究组患者则予以沙库巴曲缬沙坦钠片治疗,比较两组患者疗效、神经内分泌激素指标[去甲肾上腺素(NA)、醛固酮(ALD)、血管紧张素Ⅱ(AngⅡ)]和心功能指标[超敏心肌肌钙蛋白T(hs-cTnT)、N-末端脑钠肽前体(NT-proBNP)、左房内径(LAD)、左室舒张末期内径(LVEDD)以及左室射血分数(LVEF)]。记录两组患者心血管不良事件发生情况。结果:研究组患者治疗12周后总有效率为90.91%(50/55),显著高于对照组患者的75.93%(41/54)(P<0.05)。两组治疗12周后ALD、NA、AngⅡ均下降,且研究组低于对照组(P<0.05)。两组治疗12周后hs-cTnT、NT-proBNP、LVEDD、LAD均下降,且研究组低于对照组(P<0.05);LVEF升高,且研究组高于对照组(P<0.05)。两组心血管不良事件发生率对比无差异(P>0.05)。结论:沙库巴曲缬沙坦钠片治疗高原地区CHF患者,疗效显著,可有效改善神经内分泌激素水平和心功能,且不增加心血管不良事件发生率,临床应用价值较高。
Objective:To investigate the effect of sacubatrovalsartan sodium in the treatment of chronic heart failure(CHF)at high altitude and its influence on neuroendocrine hormone and cardiac function.Methods:From March 2017 to June 2019,109 patients with CHF who were admitted to our hospital were selected.Patients were randomly divided into control group(n=54)and study group(n=55)according to the method of random number table.Patients in the control group were treated with valsartan,while patients in the study group were treated with sodium sakubatrovalsartan.The curative effect,neuroendocrine hormone indexes[norepinephrine(NA),aldosterone(ALD),angiotensinⅡ(AngⅡ)]and cardiac function indexes[high sensitivity cardiac troponin T(hs-cTnT),N-terminal pro brain natriuretic peptide(NT-proBNP),left atrial diameter(LAD),left ventricular end diastolic diameter(LVEDD),and left ventricular ejection fraction(LVEF)]were compared between the two groups.The incidence of cardiovascular adverse events of the two groups was recorded.Results:The total effective rate of the study group was 90.91%(50/55)at 12 weeks after treatment,which was significantly higher than75.93%(41/54)of the control group(P<0.05).12 weeks after treatment,ALD,NA,AngⅡdecreased in the two groups,and those of the study group were lower than those of the control group(P<0.05).12 weeks after treatment,hs-cTnT,NT-proBNP,LVEDD and LAD were all decreased of the two groups,and those of the study group were lower than those of the control group(P<0.05).The LVEF increased,and that of the study group was higher than that of the control group(P<0.05).There was no difference in the incidence of cardiovascular adverse events between the two groups(P>0.05).Conclusion:Sacubatrovalsartan sodium is effective in the treatment of CHF at high altitude.It can effectively improve the neuroendocrine hormone and cardiac function without increasing the incidence of adverse events.It has a high clinical application value.
作者
张璐
常彩莲
王武
王思雯
孙丽娜
李茜
温元善
ZHANG Lu;CHANG Cai-lian;WANG Wu;WANG Si-wen;SUN Li-na;LI Xi;WEN Yuan-shan(Department of Internal Medicine-Cardiovascular,Xining First People's Hospital,Xining,Qinghai,810001,China;Department of Geriatrics,Xining First People's Hospital,Xining,Qinghai,810001,China;Department of Ultrasonography,Xining First People's Hospital,Xining,Qinghai,810001,China;Department of Internal Medicine-Cardiovascular,West China Hospital of Sichuan University,Chengdu,Sichuan,610065,China)
出处
《现代生物医学进展》
CAS
2021年第12期2350-2353,2367,共5页
Progress in Modern Biomedicine
基金
青海省科技计划项目(2014-ZJ-741)。
关键词
沙库巴曲缬沙坦钠片
高原地区
慢性心力衰竭
疗效
神经内分泌激素
心功能
Sacubatrovalsartan sodium tablets
High altitude
Chronic heart failure
Efficacy
Neuroendocrine hormone
Heart function
